— KB-0742 continues to demonstrate a manageable safety and tolerability profile with no grade 3/4 neutropenia observed — — KB-0742 continues to show dose linear pharmacokinetics up to 80mg three-days-on, four-days-off dose, including increased target engagement at the 80mg vs. 60mg doses — — The escalation cohort at 80mg four-days-on, three-days-off is currently enrolling, and the expansion cohort at this dose is expected to begin enrollment in the third quarter of 2024 — SAN MATEO, Calif. and CAMBRIDGE, Ma ...